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Abstract
Vibrio cholerae O1 biotype El Tor producing Haitian variant
Cholera Toxin (HCT) and showing reduced susceptibility to
ciproﬂoxacin caused a cholera outbreak associated with a high
case fatality rate (4.5) in India. HCT-secreting strains responsible
for severe cholera epidemics in Orissa (India), Western Africa and
Haiti were associated with increased mortality. There is a pressing
need for an integrated multidisciplinary approach to combat
further spread of newly emerging variant strains. The therapeutic
effect of ciproﬂoxacin was diminished whereas use of doxycycline
in moderate to severe cholera patients was found to be effective in
outbreak management.
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It is evident from recent cholera outbreaks that mortality
following the disease has far exceeded the international target
of ≤1% [1]. The variation in biotype of the causative agent
Vibrio cholerae O1 and acquisition of different drug resistance
patterns are responsible for the emergence of new strains that
result in higher case fatality rates and make it difﬁcult to
formulate outbreak control policies. The hybrid property of
V. cholerae O1 El Tor (carrying cholera toxin (CT) of the
classical type) is known for its evolutionary ﬁtness and
heightened virulence. In addition, an important alteration is
the emergence of a variant cholera toxin, now termed Haitian
cholera toxin (HCT), ﬁrst reported by us from a large cholera
outbreak in 2007 in Orissa, India, and subsequently reported
by others from Western Africa and Haiti [2–5]. The HCT
variants carrying mutated signal peptide were associated with a
higher severity of the disease in these outbreaks.
Recently, in May 2012, a cholera outbreak hit the Yavatmal
district of Maharashtra in India, with a case fatality rate of 4.5%.
The WHO prescribes use of oral rehydration therapy in
cholera treatment and recommends antibiotics only in severe
cases (www.who.int/mediacentre/factsheets/fs107/en/index.
html). Due to the high mortality, patients were treated with
oral rehydration therapy followed by oral administration of
ciproﬂoxacin antibiotics for moderate to severe cases [6]. The
patients treated with ciproﬂoxacin had a longer duration (5–
6 days) of diarrhoea. After calculation of MIC for ciproﬂoxacin,
doxycycline was prescribed for further treatment and the
patients experienced a shorter duration (3–4 days) of diar-
rhoea. There were no further casualties after the introduction
of doxycycline into the treatment regime. However, the
disease remains persistent in the area after the outbreak as
recurrence of the cholera cases is frequently reported in
different areas of the district. A total of 26 outbreak/clinical
V. cholerae strains collected from the different affected areas
were selected for detailed characterization. The strains were
identiﬁed as V. cholerae O1, Ogawa serotype and El Tor
biotype. The sequencing of ctxB revealed His20 to Asn mutation
indicative of the newly assigned HCT type of cholera toxin.
The strains were tested for susceptibility to other
antimicrobials using the disc diffusion method according to
the Clinical and Laboratory Standards Institute (CLSI) USA
guidelines (2010) and for the underlying drug resistance
determinants. The CLSI breakpoints speciﬁc for V. cholerae
were used where available. For drugs lacking such criteria,
we applied CLSI criteria for Enterobacteriaceae or the
manufacturer’s criteria. The strains were found to be resistant
to the antibiotics ampicillin, nalidixic acid, polymixin B,
streptomycin and sulfamethoxazole/trimethoprim, and sensi-
tive to tetracycline, ciproﬂoxacin, azithromycin and imipenam.
Remarkably, the strains showed reduced susceptibility to
ciproﬂoxacin (MIC 0.5 lg/mL). The partial sequencing of the
gyrA and parC genes revealed mutation in gyrA (Ser83 to Ile)
and in parC (Ser85 to Leu) known to be responsible for
resistance/reduced susceptibility towards quinolone/ﬂuroqui-
nolone in V. cholerae (Genbank accession number
JX464656-63 and reference [7]). Moreover, the strains carried
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multidrug-resistance elements (i.e. class I integrons and SXT
constins harbouring antibiotic resistance genes aadA2 and strA
(streptomycin), dfrA1 (trimethoprim) and sulII (sulfomethox-
azole) as conﬁrmed by PCR).
The use of effective drugs in cholera shortens the duration
of illness and decreases the shedding of bacterium, which leads
to reduction in secondary cases. Ciproﬂoxacin, doxycycline
and azithromycin are effective drugs of choice to be used in the
treatment of cholera [8]. Single doses of ciproﬂoxacin were
reported to be better than single doses of doxycycline in the
eradication of the cholera bacterium from stools [9]. Cipro-
ﬂoxacin also covers most of the antimicrobials prescribed with
or without diagnostics in India. The reduced susceptibility to
ﬂuoroquinolones has been reported to be the cause of
treatment failure with ciproﬂoxacin [8].
While considering cholera management, the emergence of
novel pathogenic stains with widespread antibiotic resistance
presents the greatest challenges for the developing countries.
The WHO reported that patients infected with multi-
drug-resistant El Tor variant strains presented excessive
purging and required more intravenous ﬂuids for cure and
longer hospitalization. Thus the outbreak size, duration and
case fatality rates were increased. This is the ﬁrst report of the
presence of HCT-producing strains associated with the
outbreak in Maharashtra, south western India. The HCT
variant was ﬁrst identiﬁed in Orissa (2007) but the strains
were sensitive to ciproﬂoxacin at that time [2]. However, the
HCT-producing strains with reduced susceptibility to cipro-
ﬂoxacin and having similar mutations in the gyrA and parC genes
were noticed in recent large cholera epidemics in Western
Africa and Haiti [4,10]. All three HCT-mediated epidemics
were associated with severe diarrhoea and enhanced rate of
mortality. Ciproﬂoxacin resistance was previously reported in
the Indian subcontinent [7]. This study suggests that the
HCT-producing El Tor strains with reduced susceptibility to
ciproﬂoxacin are spreading to other regions also. Although it is
difﬁcult to rule out the persistence of the earlier strains with
increasing antibiotic resistance in the Indian subcontinent, the
identity of their toxin with HCT suggests the possible
relationship of these strains. Both emergence of drug
resistance and a CT variant hamper the outbreak control
policies, which is a serious concern for the future. Implemen-
tation of reassigned guidelines of susceptibility breakpoints for
ciproﬂoxacin and closely monitoring its use can prevent a
further rise in resistance. The development and implementa-
tion of an integrated multidisciplinary approach at a global level
is of utmost importance to combat the dissemination of newly
emerging variant strains. The study also suggests the use of
effective antibiotics in moderate to severe cases of cholera for
the management of an outbreak-like situation.
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